i believe in some interviews with AT, he's stated mcrpc for radiopharm could be 5b and potentially double if they can move above chemo in therapy lines.
this article forecast pluvicto sales in a pretaxane and post taxane market, with a predicted 20% US penetration and 15% worldwide penetration, post taxane ~1b sales and pre taxane ~2.3b on top.
CU6 Price at posting:
$6.21 Sentiment: None Disclosure: Held
